The Wistar Institute Proteomics Facility

Hattie Hickle

🇨🇭 Switzerland

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Tony Muller

🇦🇺 Australia

9.1

Reviewed: April 6, 2024

• - HTA Submission
• - 8 weeks February - March 2024
• - Biotech Company

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Robyn Moore

🇩🇪 Germany

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Darrell Mayer

🇷🇺 Russia

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.

Everett Schoen

🇲🇽 Mexico

9.1

Reviewed: September 5, 2024

• - Pharmacovigilance Services
• - Ongoing
• - Pharmaceutical Company

The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.

Tim Smitham

🇫🇷 France

9.2

Reviewed: August 20, 2024

• - Regulatory Strategy Consulting
• - 4 weeks July - August 2024
• - Biotech Startup

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Dr. Ora Vandervort

🇬🇧 United Kingdom

5.4

Reviewed: October 3, 2024

• - Process Development
• - 14 weeks June - September 2024
• - Biotech Company

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.